A clinical trial to test a gene therapy treatment for a rare liver disease
(AFM-T é l é thon) G é n é thon, a laboratory created by AFM-T é l é thon, starts a European phase I/II clinical trial to test a treatment for Crigler-Najjar Syndrome, a rare liver disease. The trial, sponsored by G é n é thon, will include 17 patients in four centres in Europe, and will assess safety and therapeutic efficacy of the gene therapy product developed by G é n é thon.
Source: EurekAlert! - Biology - Category: Biology Source Type: news
More News: Biology | Clinical Trials | Gene Therapy | Genetics | Laboratory Medicine | Liver | Liver Disease | Urology & Nephrology